Cytodyn Inc.
USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).
The verdict
According to USPTO PatentsView, Cytodyn ranks #34,926 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.
- #34,926
- of 49,997 US assignees by volume
- 25th percentile
- by Innovation Score (27.7/100)
- 15.0
- avg claims per patent
- +33%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R34926 · US Corporation #34,926 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #34,926/49,997
- PHOTO-FINISH Cybrook
- CPC-NARROW C07K · 4 areas
- INNOV-THIN 27.7/100
- CLAIMS-RICH 15.0 claims/avg
- TYPE-USCORP US Corporation
- VEL-UP +33% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Cybrook Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Cytodyn’s 27.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Cytodyn
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Cytodyn · this assignee 28
Cytodyn · this assignee
28 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Cytodyn's Innovation Score is 27.7/100 (25th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Cytodyn?
Each dot is one of Cytodyn’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cytodyn’s own 15.0 claims/patent is ABOVE the 10.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Cytodyn's grants concentrate
Cytodyn Inc. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2016. By volume, Cytodyn sits between Cybrook Inc. and D3F, LLC.
Cytodyn's three-year grant acceleration
Cytodyn Inc. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Cytodyn's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cybrook
Cybrook Inc.
7 patents
- Cyera
Cyera, Ltd.
7 patents
- Cygnus Medical
Cygnus Medical, LLC
7 patents
- Cynetic Designs
Cynetic Designs Ltd.
7 patents
- Cytune Pharma
Cytune Pharma
7 patents
- D R Nano
D. R. Nano Co., Ltd.
7 patents
- D F Omer
D.F. Omer Ltd
7 patents
- D3F
D3F, LLC
7 patents
- Cytodyn ◀
Cytodyn Inc.
7 patents
What this shows Cytodyn holds 7 patents at rank #34,923, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Cytodyn
By rank, the assignees closest to #34,923 in granted patent volume.
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Cytodyn's primary technology class.
- The Regents of the University of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies GmbH 678 in class
- Genentech, Inc. 565 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 513 in class
- The Trustees of the University of Pennsylvania 501 in class
- Novartis AG 407 in class
- The Board of Trustees of the Leland Stanford Junior University 400 in class
Cytodyn's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
28 25th percentile higher than 25% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 14.3% |
| 2018 | 1 | 14.3% |
| 2019 | 1 | 14.3% |
| 2020 | 1 | 14.3% |
| 2021 | 1 | 14.3% |
| 2023 | 2 | 28.6% |
Which technologies does Cytodyn Inc. patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Cytodyn Inc.'s patent record in context - here's where to go next.
- Cytodyn Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
- Ranked #34,926 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Cytodyn Inc. against Cybrook Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 27.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.